Diet and WB-EMS Effects in Obesity (DEMO-OB)
Effects of Energy-Restricted Diet and Whole-Body Electromyostimulation (WB-EMS) on Myokine-Adipokine Interaction, Appetite Regulation, and Body Composition in Obese Individuals: A Randomized Controlled Trial
Obesity is a major global health problem associated with metabolic dysfunction, altered adipokine signaling, and impaired appetite regulation. Conventional weight loss strategies such as calorie restriction often result in compensatory physiological adaptations, including increased appetite and loss of lean body mass, which may limit long-term effectiveness.
Whole-body electromyostimulation (WB-EMS) is an emerging, time-efficient intervention that induces simultaneous muscle activation and may improve metabolic health. However, the underlying molecular mechanisms, particularly the interaction between myokines and adipokines, remain insufficiently understood.
This randomized controlled trial aims to investigate the effects of an energy-restricted diet combined with WB-EMS on myokine-adipokine interaction, appetite regulation, and body composition in obese individuals. Participants will be randomly assigned to either a diet-only group or a diet plus WB-EMS group for 8 weeks.
Primary outcomes include changes in serum irisin levels. Secondary outcomes include myostatin, leptin, adiponectin, FGF-21, ghrelin, GLP-1, body composition parameters, and eating behavior. The findings of this study are expected to provide novel insights into the physiological and molecular effects of WB-EMS as a complementary strategy in obesity management.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Muharrem Gökhan Beydağı, PhD
- Telefonnummer: +905323581105
- E-mail: mgbeydagi@firat.edu.tr
Undersøgelse Kontakt Backup
- Navn: Murat Acik, PhD
- Telefonnummer: +90 544 111 81 24
- E-mail: macik@firat.edu.tr
Studiesteder
-
-
-
Diyarbakır, Tyrkiet (Türkiye)
- Dicle University
-
Kontakt:
- Feray Cagiran Yilmaz, assistant professor
- E-mail: feraycagiran@hotmail.com
-
Elâzığ, Tyrkiet (Türkiye)
- Firat University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Age between 18 and 65 years
- Body mass index (BMI) ≥ 30 kg/m²
- Sedentary lifestyle (less than 2 hours of structured exercise per week)
- Willingness to participate and provide written informed consent
Exclusion Criteria:
- Presence of pacemaker or implantable cardioverter-defibrillator
- Known cardiovascular disease or severe chronic illness
- Pregnancy or breastfeeding
- Uncontrolled diabetes or severe metabolic disorders
- Active malignancy or cancer treatment
- Severe renal or hepatic failure
- Acute infection or inflammatory disease
- Orthopedic conditions limiting physical activity
- Use of medications affecting body composition or appetite (e.g., corticosteroids, weight-loss drugs)
- Regular resistance training within the last 3 months
- Substance abuse, including alcohol or drug dependency
- Psychiatric or cognitive conditions affecting adherence to the study protocol
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Diet Only
Participants receive an individualized energy-restricted diet program.
|
A personalized diet with approximately 750 kcal/day energy deficit.
|
|
Eksperimentel: Diet + WB-EMS
Participants receive an energy-restricted diet combined with whole-body electromyostimulation (WB-EMS).
|
A personalized diet with approximately 750 kcal/day energy deficit.
Whole-body electromyostimulation applied 2-3 times per week for 8 weeks under supervision.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in serum irisin levels
Tidsramme: Baseline to 8 weeks
|
Assessment of change in circulating irisin levels measured by ELISA.
|
Baseline to 8 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in serum myostatin levels
Tidsramme: Baseline to 8 weeks
|
Assessment of change in circulating myostatin levels measured by ELISA.
|
Baseline to 8 weeks
|
|
Change in serum leptin levels
Tidsramme: Baseline to 8 weeks
|
Assessment of change in circulating leptin levels.
|
Baseline to 8 weeks
|
|
Change in serum adiponectin levels
Tidsramme: Baseline to 8 weeks
|
Assessment of change in circulating adiponectin levels.
|
Baseline to 8 weeks
|
|
Change in serum FGF-21 levels
Tidsramme: Baseline to 8 weeks
|
Assessment of change in circulating fibroblast growth factor-21 levels.
|
Baseline to 8 weeks
|
|
Change in serum ghrelin levels
Tidsramme: Baseline to 8 weeks
|
Assessment of change in circulating ghrelin levels.
|
Baseline to 8 weeks
|
|
Change in serum GLP-1 levels
Tidsramme: Baseline to 8 weeks
|
Assessment of change in circulating GLP-1 levels.
|
Baseline to 8 weeks
|
|
Change in fat mass
Tidsramme: Baseline to 8 weeks
|
Assessment of change in total body fat mass measured by bioelectrical impedance analysis (BIA).
|
Baseline to 8 weeks
|
|
Change in fat-free mass
Tidsramme: Baseline to 8 weeks
|
Assessment of change in fat-free mass measured by bioelectrical impedance analysis (BIA).
|
Baseline to 8 weeks
|
|
Change in body fat percentage
Tidsramme: Baseline to 8 weeks
|
Assessment of change in body fat percentage measured by bioelectrical impedance analysis (BIA).
|
Baseline to 8 weeks
|
|
Change in eating behavior scores
Tidsramme: Baseline to 8 weeks
|
Assessment of eating behavior using the Three-Factor Eating Questionnaire-Revised 21 (TFEQ-R21).
The questionnaire evaluates cognitive restraint, uncontrolled eating, and emotional eating behaviors.
Scores range from 21 to 84, with higher scores indicating more problematic eating behaviors.
|
Baseline to 8 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- FU_MGBeydagi_EMS_B_2026/05
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .